Could you give us a brief description of your company and explain the reasons that led you to establish it up?
ViroStatics srl (LTD), is a private capital company, with its head office in Sassari and the Research and Development Laboratories in the headquarters of the Scientific and Technological Park of Porto Conte Ricerche in Sardinia.
ViroStatics is inspired by a non ripetitive and traditional concept of R&D which aims to develop innovative drugs for therapeutic indications that lack in effective treatments.
The main objective of Virostatics is the development of drugs in the field of cancer and viral infections, which clearly shows a medical need that currently available drugs cannot meet.
The Management is made up of an international team with countless years of experience in the pharmaceutical sector. Over the course of their careers, members of the management have worked with or within large international pharmaceutical companies, gaining extensive experience in the field of preclinical and clinical drug development. Some of them have already successfully concluded important out-licensing and M&A deals.
Some of the drugs you are working on are in preclinical phase. When do you think they will be accessible and how will they be placed on the market?
The leading compound of ViroStatics is currently in advanced preclinical phase and differs from other competitors for the uniqueness of the mechanism of action, better selectivity, greater effectiveness and tolerance. Moreover, it is also active against tumors resistant to other drugs and it showed synergic effects in combination with other anticancer drugs currently on the market.
We expect to complete the IND within 12-18 months to the achievement of the next funding round.
The first therapeutic indication will be metastatic breast cancer (HR + HER2- PIK3CA +) that has developed resistance to current CDK4 / 6 inhibitor drugs (plabociclib, ribociclib and abemaciclib). It is a market which, in the US alone, is expected to reach over $ 5 billion by 2025.